公开(公告)号：EP2360182A1

公开(公告)日：2011-08-24

申请号：EP11000692.1

申请日：2007-11-13

申请人： Functional Genetics, Inc.

发明人： Duan, Roxanne ,  Kinch, Michael ,  Goldblatt, Michael

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61P31/12

CPC分类号： C07K16/18

摘要： The invention provides for inhibition of viral disease by the provision to a mammalian host of antibodies directed against an escort protein like Tsg101. These proteins appear on the surface of a cell, and thus can be bound by circulating antibodies thereto. By binding escort proteins on the cell surface, budding of viral particles is inhibited. The virus infects the initial cells, but cannot escape that cell to infect the body en masse.

摘要翻译： 本发明通过向哺乳动物宿主提供针对诸如Tsg101之类的护送蛋白的抗体来提供对病毒性疾病的抑制。 这些蛋白质出现在细胞表面，因此可以通过循环其抗体而结合。 通过在细胞表面结合护送蛋白，病毒颗粒的出芽被抑制。 病毒感染初始细胞，但不能逃避该细胞大量感染身体。

公开(公告)号：EP2348847A1

公开(公告)日：2011-08-03

申请号：EP09824200.1

申请日：2009-10-30

申请人： Medivation Technologies, Inc.

发明人： HUNG, David, T. ,  PROTTER, Andrew, Asher ,  JAIN, Rajendra, Parasmal ,  CHAKRAVARTY, Sarvajit ,  GIORGETTI, Marco

IPC分类号： A01N43/00 ,  A01N43/46 ,  A61K31/55

CPC分类号： C07D487/04 ,  A61K31/55 ,  C07D471/04

摘要： This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1, 2,3,4,5, 6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.

公开(公告)号：EP2346332A1

公开(公告)日：2011-07-27

申请号：EP09824199.5

申请日：2009-10-30

申请人： Medivation Technologies, Inc.

发明人： HUNG, David, T. ,  PROTTER, Andrew, Asher ,  JAIN, Rajendra, Parasmal ,  CHAKRAVARTY, Sarvajit ,  GIORGETTI, Marco

IPC分类号： A01N43/42 ,  A61K31/44 ,  A61K31/405

CPC分类号： C07D471/04 ,  C07D401/14

摘要： This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

公开(公告)号：EP2335696A1

公开(公告)日：2011-06-22

申请号：EP10011644.1

申请日：2006-06-07

申请人： ORION CORPORATION

发明人： Vahervuo, Kari

IPC分类号： A61K31/275 ,  A61K31/195 ,  A61K9/28 ,  A61K9/48 ,  A61K9/16

CPC分类号： A61K31/277 ,  A61K9/1641 ,  A61K9/1652 ,  A61K9/2853 ,  A61K9/48 ,  A61K31/195 ,  A61K31/275 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to an oral dosage form of entacapone and to methods for the preparation thereof.

摘要翻译： 本发明涉及恩他卡朋的口服剂型及其制备方法。

公开(公告)号：EP1634877B1

公开(公告)日：2011-06-22

申请号：EP04254939.4

申请日：2004-08-17

申请人： Simpson Biotech Co., Ltd.

发明人： Hattori, Massao ,  Sheu, Chia-Chin

IPC分类号： C07D307/34 ,  C07D307/60 ,  C07D207/44 ,  C07D207/46 ,  A61K31/341 ,  A61K31/4015 ,  A61K36/06 ,  C12N1/14

CPC分类号： C07D207/444 ,  C07D207/46 ,  C07D307/34

公开(公告)号：EP2331081A1

公开(公告)日：2011-06-15

申请号：EP09816612.7

申请日：2009-04-17

申请人： Tower Laboratories, Inc.

发明人： RAU, Allen, H.

IPC分类号： A61K9/46

CPC分类号： C11D3/0052 ,  C11D3/10 ,  C11D3/128 ,  C11D7/10 ,  C11D7/12 ,  C11D7/14 ,  C11D11/0052

摘要： This invention provides a tablet that effervesces and significantly warms the water that it is dissolved in. The effervescence acts to break up the tablet allowing an exothermic material to rapidly dissolve releasing its heat of solution. The invention is unique in that no organic acid is required to form a conventional effervescent couple.

公开(公告)号：EP2316459A1

公开(公告)日：2011-05-04

申请号：EP10010732.5

申请日：2003-07-29

申请人： Rigel Pharmaceuticals, Inc.

发明人： Singh, Rajinder ,  Argade, Ankush ,  Payan, Donald G. ,  Clough, Jeffrey ,  Keim, Holger ,  Sylvain, Catherine ,  Li, Hui ,  Bhamidipati, Somasekhar

IPC分类号： A61K31/506 ,  A61K31/519 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： A61K31/506 ,  A61K31/519 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

摘要： The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

摘要翻译： 本发明提供用2,4-嘧啶二胺化合物治疗或预防自身免疫疾病的方法，以及治疗，预防或改善与这些疾病相关的症状的方法。 可以用化合物治疗或预防的自身免疫性疾病的具体实例包括类风湿性关节炎和/或其相关症状，系统性红斑狼疮和/或其相关症状和多发性硬化症和/或其相关症状。

公开(公告)号：EP2283863A1

公开(公告)日：2011-02-16

申请号：EP10011510.4

申请日：1999-10-08

申请人： QLT Inc.

发明人： Margaron, Philippe, Maria, Clotaire ,  Leong, Simon ,  Richter, Anna, M. ,  Levy, Julia, G.

IPC分类号： A61K41/00

CPC分类号： A61K41/0057 ,  A61K41/0071

摘要： The invention provides a method to inhibit the formation of neovasculature while maintaining viability of the underlying tissue by subjecting a subject in which angiogenesis is to be inhibited to sublethal photodynamic therapy. The invention also provides a model for assessing sublethal PDT protocols to inhibit angiogenesis in particular target tissues.

摘要翻译： 本发明提供一种抑制新血管形成的方法，同时通过对其中血管生成被抑制的受试者进行亚致死性光动力学治疗来维持潜在组织的活力。 本发明还提供了用于评估亚致死性PDT方案以抑制特别是靶组织中的血管生成的模型。

公开(公告)号：EP2261286A1

公开(公告)日：2010-12-15

申请号：EP10009107.3

申请日：2003-05-07

申请人： Sony Corporation

发明人： Sato, Noritaka ,  Noguchi, Tsutomu ,  Mori, Hiroyuki

IPC分类号： C08L67/04 ,  C08K5/20

CPC分类号： C08K5/0083 ,  C08L67/04

摘要： The present invention provides a resin composition for molding, added with a nucleating agent suitable for promoting crystallization of polyester capable having a crystal structure, and in particular of biodegradable polyester, and also provides a molded product containing the resin composition for molding thus improved in the crystallinity. The resin composition is characterized by comprising polylactic acid and either
a cyclic compound expressed by general formula (I) below:

[where each of A 1 , A 2 , A 4 and A 5 is independently -CO- or -NH-, each of A 3 and A 6 is independently hydrogen, halogen, an optionally-substituted aliphatic group or an optionally-substituted aromatic group] and having both of -CO- and -NH- in the molecule, or
a mixture of (i) a cyclic compound having -CO- but no NH in the molecule and (ii) a cyclic compound having no -CO- but NH in the molecule.

摘要翻译： 本发明提供了一种成型用树脂组合物，添加有适于促进具有晶体结构的聚酯的结晶的成核剂，特别是可生物降解的聚酯的结晶性树脂组合物，还提供了含有模塑用树脂组合物的成型体， 结晶。 该树脂组合物的特征在于包含聚乳酸和由下述通式（I）表示的环状化合物：其中A 1，A 2，A 4和A 5各自独立地为-CO-或-NH-，各自为 A 3和A 6独立地为氢，卤素，任选取代的脂族基团或任选取代的芳族基团]，并且在分子中具有-CO-和-NH-，或（i）环状化合物 在分子中具有-CO-但不具有NH，和（ii）在分子中不具有-CO-但NH的环状化合物。

公开(公告)号：EP2244708A1

公开(公告)日：2010-11-03

申请号：EP09704753.4

申请日：2009-01-26

申请人： Medivation Technologies, Inc.

发明人： HUNG, David, T. ,  PROTTER, Andrew, Asher ,  CHAKRAVARTY, Sarvajit ,  JAIN, Rajendra, Parasmal

IPC分类号： A61K31/4745 ,  C07D471/02

CPC分类号： C07D487/14 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04

摘要： This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.